Patients’ characteristics at CYC initiation. Values are n (%) unless otherwise specified.
| Characteristics | Whole Cohort, n = 110 | Systemic Vasculitis, n = 81 | SLE, n = 29 |
|---|---|---|---|
| Female | 60 (54.5) | 37 (45.7) | 23 (79.3) |
| Age, yrs, mean ± SD | 55.7 ± 18.8 | 62.2 ± 15.4 | 37.3 ± 15.0 |
| Medical history | |||
| Diabetes | 8 (7.3) | 8 (9.9) | 0 |
| Cancer | 6 (5.5) | 6 (7.4) | 0 |
| Varicella a | 71 (100) | 49 (100) | 22 (100) |
| Zoster b | 12 (14.6) | 8 (14.0) | 4 (16.0) |
| Kidney failure c | 52 (49.5) | 41 (53.2) | 11 (39.3) |
| Lymphopenia c | |||
| < 1000/µl | 36 (34.3) | 22 (28.6) | 14 (50.0) |
| < 500/µl | 9 (8.6) | 4 (5.2) | 5 (17.9) |
| Previous treatments | |||
| Corticosteroids | 40 (36.4) | 20 (24.7) | 20 (69.0) |
| Other immunosuppressive drugs | 26 (23.6) | 9 (11.1) | 17 (58.6) |
| AZA | 10 (9.1) | 5 (6.2) | 5 (17.2) |
| MMF | 13 (11.8) | 1 (1.2) | 12 (41.4) |
| MTX | 8 (7.3) | 4 (4.9) | 4 (13.8) |
| RTX | 1 (0.9) | 0 | 1 (3.4) |
| CSA | 1 (0.9) | 0 | 1 (3.4) |
| BEL | 2 (1.8) | 0 | 2 (6.9) |
| Treatments received in the year after CYC | |||
| Plasmapheresis | 20 (18.2) | 20 (24.7) | 0 |
| Corticosteroids | 110 (100) | 81 (100) | 29 (100) |
| Other immunosuppressive drugs | 96 (87.3) | 69 (85.2) | 27 (93.1) |
| AZA | 55 (50.0) | 41 (50.6) | 14 (48.3) |
| MMF | 20 (18.2) | 6 (7.4) | 14 (48.3) |
| MTX | 4 (3.6) | 3 (3.7) | 1 (3.4) |
| RTX | 26 (23.7) | 25 (30.9) | 1 (3.4) |
| BEL | 1 (0.9) | 0 | 1 (3.4) |